AZD0328
AZD0328 is a drug candidate that was developed by AstraZeneca. It is a selective agonist for the alpha-7 nicotinic acetylcholine receptor (α7 nAChR), which is a type of ionotropic receptor. AZD0328 has been studied for its potential use in the treatment of schizophrenia and Alzheimer's disease.
Chemistry[edit]
AZD0328 is a quaternary ammonium compound. It is a derivative of tropane, a bicyclic organic compound that is a foundational structure for many alkaloids. The drug's chemical structure also includes a phenyl ring, a common feature in many pharmaceutical drugs.
Pharmacology[edit]
As an agonist for the α7 nAChR, AZD0328 has the potential to enhance cognitive function. The α7 nAChR is a ligand-gated ion channel that is involved in various cognitive processes, including attention, learning, and memory. By binding to this receptor, AZD0328 can increase the flow of ions across the cell membrane, which can enhance neuronal signaling and improve cognitive function.
Clinical Trials[edit]
AZD0328 has undergone Phase I clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. However, as of 2021, no further development has been reported.
Potential Therapeutic Uses[edit]
AZD0328 has been studied for its potential use in the treatment of cognitive impairments associated with schizophrenia and Alzheimer's disease. Both of these conditions are characterized by deficits in cognitive function, and the α7 nAChR has been identified as a potential target for therapeutic intervention.
See Also[edit]
